Mavacamten HCM denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for mavacamten hcm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Mavacamten — and How to Obtain It or Appeal a Denial

Mavacamten is a specialty cardiac medication approved for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aetna, like virtually all commercial insurers, requires prior authorization (PA) before covering mavacamten. The PA process exists to confirm that the prescription meets Aetna's clinical criteria — typically including confirmation of the oHCM diagnosis, assessment of symptomatic severity, documentation of prior therapy, and specialist prescriber requirements. A prior-auth-required denial at the pharmacy is not a final coverage decision; it is a notification that the PA process must be completed first.

## Why Prior-Auth Denials Are Appealable (and Avoidable)

If a PA was submitted and denied on clinical grounds, that denial is a formal adverse benefit determination with full appeal rights. If the PA was never submitted, the prescriber's office can initiate it. If the PA was denied due to missing information, supplementing the submission with complete documentation often results in approval without a formal appeal. Understanding the exact reason for denial is the critical first step.

## Federal Appeal Framework

• PA resubmission: If the initial PA was denied for missing documentation, a corrected submission with complete records may be faster than a formal appeal.
• Internal appeal: If the PA was denied on clinical criteria, file a formal internal appeal within the window in the denial letter.
• External review (ACA §2719): After exhausting internal appeals, most non-grandfathered plan members may request independent external review within approximately four months of the final denial.
• ERISA §503: Employer-plan members are entitled to a full-and-fair review.
• Expedited review: If the patient is acutely symptomatic or a gap in therapy poses serious risk, request expedited review — response required within 72 hours.

## Documentation to Gather

• Confirmed diagnosis: Echocardiographic reports and specialist records confirming symptomatic oHCM with obstruction.
• Symptom documentation: Chart notes recording functional class, exertional symptoms, and how they affect daily activity and quality of life.
• Prior therapy history: Records for all previously tried oHCM medications — names, dates, duration, and documented outcomes or reasons for discontinuation — per whatever Aetna's PA criteria require.
• Specialist prescriber credentials: Confirmation that the prescriber meets any specialty requirements in Aetna's PA criteria (typically a cardiologist or HCM-treating specialist).
• Prescriber medical-necessity letter: A letter directly addressing each PA criterion, confirming that the patient meets the FDA-approved indication, and referencing current cardiology society guidelines.

## Criteria-Mapping Structure

Obtain Aetna's current PA criteria for mavacamten. Address each item:

| PA Criterion | Supporting Documentation | |---|---| | Diagnosis of symptomatic oHCM confirmed | [Echocardiogram report, ICD code, specialist note] | | Symptomatic burden documented | [Functional class per chart, symptom description] | | Prior therapy tried/failed or contraindicated | [Medication records with dates and outcomes] | | Prescriber is appropriate specialist | [Cardiologist note, practice credentials] | | Dose and regimen consistent with FDA label | [Prescriber attestation referencing label] |

Submitting a complete, criterion-by-criterion PA packet upfront significantly reduces the rate of initial denial and makes any subsequent appeal straightforward.